LncRNA SND1-IT1 accelerates the proliferation and migration of osteosarcoma via sponging miRNA-665 to upregulate POU2F1

被引:28
作者
Jin, X. -M. [1 ]
Xu, B. [1 ]
Zhang, Y. [1 ]
Liu, S. -Y. [1 ]
Shao, J. [1 ]
Wu, L. [1 ]
Tang, J. -A. [1 ]
Yin, T. [1 ]
Fan, X. -B. [1 ]
Yang, T. -Y. [1 ]
机构
[1] Second Mil Med Univ, Gongli Hosp, Dept Orthopaed, Shanghai, Peoples R China
关键词
Osteosarcoma; LncRNA SND1-IT1; MiRNA-665; POU2F; Proliferation; Migration; PATHWAY; GROWTH; TARGET;
D O I
10.26355/eurrev_201911_19540
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
OBJECTIVE: To clarify the role of long non-coding RNA (lncRNA) SND1-IT1 in accelerating the proliferative and migratory abilities of osteosarcoma (OS) via sponging miRNA-665 to upregulate POU2F1. PATIENTS AND METHODS: The relative level of SND1-IT1 in OS tissues was determined by quantitative Real Time-Polymerase Chain Reaction (qRT-PCR). The target gene of SND1-IT1 was predicted by bioinformatics and verified by Dual-Luciferase reporter gene assay. Similarly, the target gene of miRNA-665 was identified. Correlation among SND1-IT1. miRNA-665 and POU2F1 was evaluated through linear regression test. Regulatory effects of SND1-IT1/miRNA-665/POU2F1 on cellular behaviors of MG63 and U2OS cells were evaluated. RESULTS: SND1-IT1 was upregulated in OS, knockdown of which attenuated proliferative and migratory abilities of OS cells. MiRNA-665 was the target gene of SND1-IT1, which was negatively correlated to SND1-IT1 in OS. POU2F1 was the target gene of miRNA-665. Its level was negatively regulated by miRNA-665 and positively regulated by SND1-IT1. Inhibited proliferative and migratory abilities of OS cells with SND1-IT1 knockdown were partially elevated by transfection of miRNA-665 inhibitor, and further downregulated by POU2F1 knockdown. CONCLUSIONS: LncRNA SND1-IT1 accelerates proliferative and migratory abilities of OS via sponging miRNA-665 to upregulate POU2F1, thus stimulating the progression of OS.
引用
收藏
页码:9772 / 9780
页数:9
相关论文
共 22 条
[1]   The locus of microRNA-10b A critical target for breast cancer insurgence and dissemination [J].
Biagioni, Francesca ;
Ben-Moshe, Noa Bossel ;
Fontemaggi, Giulia ;
Yarden, Yosef ;
Domany, Eytan ;
Blandino, Giovanni .
CELL CYCLE, 2013, 12 (15) :2371-2375
[2]  
Chen Z, 2018, J BUON, V23, P1816
[3]   Assessing the ceRNA Hypothesis with Quantitative Measurements of miRNA and Target Abundance [J].
Denzler, Remy ;
Agarwal, Vikram ;
Stefano, Joanna ;
Bartel, David P. ;
Stoffel, Markus .
MOLECULAR CELL, 2014, 54 (05) :766-776
[4]  
Gao KT, 2016, EUR REV MED PHARMACO, V20, P3561
[5]  
Hu XH, 2018, EUR REV MED PHARMACO, V22, P7640, DOI 10.26355/eurrev_201811_16379
[6]   Osteosarcoma: Current Treatment and a Collaborative Pathway to Success [J].
Isakoff, Michael S. ;
Bielack, Stefan S. ;
Meltzer, Paul ;
Gorlick, Richard .
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (27) :3029-U127
[7]   WHO classification of soft tissue tumours: an update based on the 2013 (4th) edition [J].
Jo, Vickie Y. ;
Fletcher, Christopher D. M. .
PATHOLOGY, 2014, 46 (02) :95-104
[8]   Molecular pathogenesis of osteosarcoma [J].
Kansara, Maya ;
Thomas, David M. .
DNA AND CELL BIOLOGY, 2007, 26 (01) :1-18
[9]   Zoledronic acid is an effective radiosensitizer in the treatment of osteosarcoma [J].
Kim, Eun Ho ;
Kim, Mi-Sook ;
Lee, Kyung-Hee ;
Koh, Jae-Soo ;
Jung, Won-Gyun ;
Kong, Chang-Bae .
ONCOTARGET, 2016, 7 (43) :70869-70880
[10]   The microRNA signatures: aberrantly expressed microRNAs in head and neck squamous cell carcinoma [J].
Koshizuka, Keiichi ;
Hanazawa, Toyoyuki ;
Fukumoto, Ichiro ;
Kikkawa, Naoko ;
Okamoto, Yoshitaka ;
Seki, Naohiko .
JOURNAL OF HUMAN GENETICS, 2017, 62 (01) :3-13